Association of Complement and MAPK Activation With SARS-CoV-2-Associated Myocardial Inflammation.
Journal
JAMA cardiology
ISSN: 2380-6591
Titre abrégé: JAMA Cardiol
Pays: United States
ID NLM: 101676033
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
pubmed:
16
12
2021
medline:
15
3
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
Myocardial injury is a common feature of patients with SARS-CoV-2 infection. However, the cardiac inflammatory processes associated with SARS-CoV-2 infection are not completely understood. To investigate the inflammatory cardiac phenotype associated with SARS-CoV-2 infection compared with viral myocarditis, immune-mediated myocarditis, and noninflammatory cardiomyopathy by integrating histologic, transcriptomic, and proteomic profiling. This case series was a cooperative study between the Ludwig Maximilian University Hospital Munich and the Cardiopathology Referral Center at the University of Tübingen in Germany. A cohort of 19 patients with suspected myocarditis was examined; of those, 5 patients were hospitalized with SARS-CoV-2 infection between March and May 2020. Cardiac tissue specimens from those 5 patients were compared with specimens from 5 patients with immune-mediated myocarditis, 4 patients with non-SARS-CoV-2 viral myocarditis, and 5 patients with noninflammatory cardiomyopathy, collected from January to August 2019. Endomyocardial biopsy. The inflammatory cardiac phenotypes were measured by immunohistologic analysis, RNA exome capture sequencing, and mass spectrometry-based proteomic analysis of endomyocardial biopsy specimens. Among 19 participants, the median age was 58 years (range, 37-76 years), and 15 individuals (79%) were male. Data on race and ethnicity were not collected. The abundance of CD163+ macrophages was generally higher in the cardiac tissue of patients with myocarditis, whereas lymphocyte counts were lower in the tissue of patients with SARS-CoV-2 infection vs patients with non-SARS-CoV-2 virus-associated and immune-mediated myocarditis. Among those with SARS-CoV-2 infection, components of the complement cascade, including C1q subunits (transcriptomic analysis: 2.5-fold to 3.6-fold increase; proteomic analysis: 2.0-fold to 3.4-fold increase) and serine/cysteine proteinase inhibitor clade G member 1 (transcriptomic analysis: 1.7-fold increase; proteomic analysis: 2.6-fold increase), belonged to the most commonly upregulated transcripts and differentially abundant proteins. In cardiac macrophages, the abundance of C1q was highest in SARS-CoV-2 infection. Assessment of important signaling cascades identified an upregulation of the serine/threonine mitogen-activated protein kinase pathways. This case series found that the cardiac immune signature varied in inflammatory conditions with different etiologic characteristics. Future studies are needed to examine the role of these immune pathways in myocardial inflammation.
Identifiants
pubmed: 34910083
pii: 2786891
doi: 10.1001/jamacardio.2021.5133
pmc: PMC8674808
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
286-297Investigateurs
Peter Boekstegers
(P)
Thomas Gehrig
(T)
Claudius Jacobshagen
(C)
Werner Moshage
(W)
Nikos Werner
(N)
Références
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
J Mol Cell Cardiol. 2015 Oct;87:38-47
pubmed: 26241845
JAMA Cardiol. 2020 Nov 1;5(11):1265-1273
pubmed: 32730619
Sci Rep. 2020 Oct 19;10(1):17597
pubmed: 33077815
Front Immunol. 2020 Sep 23;11:560381
pubmed: 33072099
Rev Physiol Biochem Pharmacol. 2016;172:77-100
pubmed: 27848025
Sci Immunol. 2021 Apr 7;6(58):
pubmed: 33827897
Clin Exp Immunol. 2017 May;188(2):183-194
pubmed: 28249350
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
Genome Res. 2015 Sep;25(9):1372-81
pubmed: 26253700
Front Immunol. 2021 Feb 26;12:627548
pubmed: 33777012
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
J Am Coll Cardiol. 2020 Sep 8;76(10):1244-1258
pubmed: 32652195
EMBO Mol Med. 2021 Aug 9;13(8):e14150
pubmed: 34133077
Nat Med. 2020 Oct;26(10):1609-1615
pubmed: 32747830
J Card Fail. 2021 Jul;27(7):727-743
pubmed: 34022400
Physiol Rev. 2010 Oct;90(4):1507-46
pubmed: 20959622
J Lab Clin Med. 1994 Apr;123(4):485-91
pubmed: 7511675
J Pathol. 1994 Aug;173(4):303-7
pubmed: 7525907
J Immunol. 2020 Sep 15;205(6):1488-1495
pubmed: 32699160
Elife. 2021 Mar 30;10:
pubmed: 33781385
Nat Commun. 2021 Jun 7;12(1):3406
pubmed: 34099652
Am J Ophthalmol. 2011 Jan;151(1):7-10.e1
pubmed: 21163373
Circulation. 2005 Feb 22;111(7):887-93
pubmed: 15699250
Mol Cell Proteomics. 2018 Dec;17(12):2534-2545
pubmed: 30385480
Nat Methods. 2020 Dec;17(12):1229-1236
pubmed: 33257825
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
JAMA Cardiol. 2020 Nov 1;5(11):1281-1285
pubmed: 32730555
Nature. 2020 Dec;588(7836):146-150
pubmed: 32726800
Nat Med. 2018 Aug;24(8):1234-1245
pubmed: 29892064
EClinicalMedicine. 2020 Nov;28:100590
pubmed: 33173853
Blood. 2009 Jan 22;113(4):887-92
pubmed: 18849484
Genomics. 1998 Jun 1;50(2):199-205
pubmed: 9653646
Mod Pathol. 2021 Jul;34(7):1345-1357
pubmed: 33727695
Front Immunol. 2021 Oct 04;12:741502
pubmed: 34671355
Springer Semin Immunopathol. 2005 Nov;27(3):286-98
pubmed: 16267649
Nature. 2021 Jul;595(7865):107-113
pubmed: 33915569
Physiol Rev. 2012 Apr;92(2):689-737
pubmed: 22535895
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nat Commun. 2019 Jun 7;10(1):2524
pubmed: 31175306
J Pathol. 2020 May;251(1):100-112
pubmed: 32154592
Nat Rev Cardiol. 2021 Mar;18(3):169-193
pubmed: 33046850
Blood. 2016 Nov 3;128(18):2218-2228
pubmed: 27683415
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828